[{"from": "human", "value": "Describe this molecule. [C][C][=Branch1][C][=O][C@][Branch2][Branch1][=Branch2][C][C@@H1][Branch2][Ring2][Branch1][C][=C][Branch1][Ring2][C][Ring1][=Branch1][C][=Branch2][Ring1][=Branch2][=C][C][=Branch1][Branch1][=C][Ring1][#Branch1][O][C][=Branch1][C][=O][C][=C][C][=C][C][=C][Ring1][=Branch1][C][Ring1][=N][=O][O][O][C@H1][C][C@@H1][Branch1][=Branch2][C@@H1][Branch1][Branch1][C][O][Ring1][=Branch1][O][O][N]"}, {"from": "gpt", "value": "The molecule is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin."}]